| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/15/2009 | CN100478033C Medicine comprising HGF gene |
| 04/15/2009 | CN100478031C The use of substituted tetracyclic imidazole derivatives as anti-histaminics |
| 04/15/2009 | CN100478022C Synergistic composition for treating hyperlipemia |
| 04/15/2009 | CN100478002C Compound medication of valerian for treating coronary heart disease, and preparation method |
| 04/15/2009 | CN100477997C Hydrophobic formulation containing total notoginseng glycosides and phospholipid and preparation method thereof |
| 04/15/2009 | CN100477995C Fortifier |
| 04/15/2009 | CN100477992C Substituted piperazine and piperidine calcium channel blockers |
| 04/15/2009 | CN100477988C Use of pogostemonis alkane type sesquiterpene compound as vegetative female sex normone |
| 04/15/2009 | CN100477985C Naoxinqing Chinese medicine dispersible tablet and its preparing process |
| 04/14/2009 | US7517989 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/14/2009 | US7517987 Interleukin converting enzyme inhibitors such as 5-Fluoro-4-oxo-3-(2-(6-oxo-6H-pyrimidin-1-yl)-butyrylamino)-pentanoic acid, administered as modulators of cell apoptosis and inflammation |
| 04/14/2009 | US7517974 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders |
| 04/14/2009 | US7517965 Non-neutralizing anti-aPC antibodies |
| 04/14/2009 | US7517962 TWEAK receptor |
| 04/14/2009 | US7517909 Using 3-amino-5-methyl-octanoic acid for therapy of psychiatric, pain and other disorders |
| 04/14/2009 | US7517907 specific activator of retinoic acid receptors subtype beta; 6-[3-adamantan-1-yl-4-(2,2-dimethyl[1,3]dioxoian-4-ylmethoxy)phenyl]naphthalene-2-carboxylic acid; useful in human or veterinary medicine; for body/hair hygiene, treating acne-prone skin, promoting hair regrowth, limiting hair loss, dry skin |
| 04/14/2009 | US7517896 e.g. methyl 4-{[(5-ethoxy-5-oxopentyl)(2-methoxyphenethyl)amino]methyl}benzoate; stimulant of guanylate cyclase; catalyse the biosynthesis of cGMP from guanosine triphosphate (GTP); cardiovascular disorders; liver fibrosis |
| 04/14/2009 | US7517892 Ligands for monoamine receptors and transporters, and methods of use thereof |
| 04/14/2009 | US7517879 Pyrrolidine derivatives as factor Xa inhibitors |
| 04/14/2009 | US7517686 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 04/14/2009 | US7517672 Nucleic acids encoding mammalian T-type calcium channels |
| 04/14/2009 | US7517661 Methods of screening for ligands for FPRL2 |
| 04/14/2009 | US7517658 Drug screening for human SNORF33 receptor agonist by contacting cells transfected with and expressing DNA encoding the human SNORF33 receptor, wherein cells prior to being transfected with the DNA do not express the human SNORF33 receptor; inflammation, infections, arthritis; autoimmune diseases |
| 04/14/2009 | US7517517 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| 04/14/2009 | CA2427817C Estrone-derivatives having cytoprotective activity |
| 04/14/2009 | CA2412213C A method for treating septic shock |
| 04/14/2009 | CA2409841C Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
| 04/14/2009 | CA2371789C Novel guanidine derivatives as inhibitors of cell adhesion |
| 04/14/2009 | CA2359440C Phenylphenanthridines with pde-iv inhibiting activity |
| 04/14/2009 | CA2337797C Naaladase inhibitors useful as pharmaceutical compounds and compositions |
| 04/14/2009 | CA2253211C Sulfonamide-substituted fused 5-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them |
| 04/14/2009 | CA2240256C Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
| 04/14/2009 | CA2170479C Benzothiophene compounds, intermediates, compositions, and methods |
| 04/09/2009 | WO2009045800A1 Treatment of cardiovascular disorders using the cell differentiation signaling protein nell1 |
| 04/09/2009 | WO2009044930A1 Pharmaceutical composition for inhibiting the accumulation of amyloid-β protein |
| 04/09/2009 | WO2009044899A1 Nucleic acid capable of regulating the proliferation of cell |
| 04/09/2009 | WO2009044788A1 Benzoxazinone derivative |
| 04/09/2009 | WO2009044787A1 Remedy for tendon rupture disease comprising tenomodulin as the active ingredient |
| 04/09/2009 | WO2009044555A1 Preparation and method of administering vaccine and iontophoresis device using the preparation |
| 04/09/2009 | WO2009044547A1 Nerve cell death inhibitor |
| 04/09/2009 | WO2009044250A1 New compounds as adenosine a1 receptor antagonists |
| 04/09/2009 | WO2009044019A2 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof |
| 04/09/2009 | WO2009044018A2 Derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 4-oxo-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics |
| 04/09/2009 | WO2009043953A1 Use of truncated ppar-alpha inhibitors in the treatment of heart failure in patients with hypertensive cardiopathy |
| 04/09/2009 | WO2009043747A2 N-heterocyclic biaryl carboxamides as ccr receptor antagonists |
| 04/09/2009 | WO2009043529A1 Thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | WO2009043528A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | WO2009043527A2 Therapeutic use of human growth hormone 1-43 |
| 04/09/2009 | WO2009043526A2 Use of gip ( 6-30) alone or in combination with hgh as a therapeutic agent |
| 04/09/2009 | WO2009043524A2 Use of a peptide as therapeutic agent |
| 04/09/2009 | WO2009043523A2 Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| 04/09/2009 | WO2009043522A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043521A2 Use of urocortin iii and urocortin i as therapeutic agents |
| 04/09/2009 | WO2009043520A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | WO2009043519A2 Use of band 3 protein and pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043518A2 Use of a combination of cart peptides as a therapeutic agent |
| 04/09/2009 | WO2009043507A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043506A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043505A2 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer |
| 04/09/2009 | WO2009043504A2 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer |
| 04/09/2009 | WO2009043481A2 Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043480A2 Use of leptin (22-56 ) as a therapeutic agent |
| 04/09/2009 | WO2009043479A2 Use of eaa-mart1 (26-35) for the treatment of human cytomegalovirus infections |
| 04/09/2009 | WO2009043478A2 Use of bubuc and optionally eaa-mart1 (26-35) as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043477A2 Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent |
| 04/09/2009 | WO2009043476A2 Neuromedin s as a therapeutic agent |
| 04/09/2009 | WO2009043469A2 Use of pneumadin as a therapeutic agent |
| 04/09/2009 | WO2009043468A2 Use of corticotropin-releasing factor as a therapeutic agent |
| 04/09/2009 | WO2009043467A1 U e of urocortin and corticotropin-releasing fact r as therapeutic agents |
| 04/09/2009 | WO2009043466A2 Therapeutic use of the peptide gluten exorphin a5 |
| 04/09/2009 | WO2009043465A2 Use of beta-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043464A2 Astressin and beta- endorphin for use as therapeutic agents |
| 04/09/2009 | WO2009043462A1 Use of neuropeptide af as a therapeutic agent |
| 04/09/2009 | WO2009043461A1 Use of a hnp-1 defensin peptide, alone or in combination with neuropeptide af, as a therapeutic agent |
| 04/09/2009 | WO2009043460A1 Use of alpha-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043459A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | WO2009043458A2 Use of oxytocin to treat many diseases |
| 04/09/2009 | WO2009043457A2 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis |
| 04/09/2009 | WO2009043456A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043455A2 Therapeutic uses of angiogenin 108-122 and gluten exorphin a5 |
| 04/09/2009 | WO2009043454A2 Use of pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043452A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | WO2009043451A2 Use of chorionic gonadotropin-beta (109-145) as a therapeutic agent |
| 04/09/2009 | WO2009043450A2 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents |
| 04/09/2009 | WO2009043449A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043448A2 Neuromedin u-25 and neuromedin s as therapeutic agents |
| 04/09/2009 | WO2009043447A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043441A1 D-ala-gln-octadecyl ester as a therapeutic agent |
| 04/09/2009 | WO2009043440A2 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
| 04/09/2009 | WO2009043439A2 Use of retrocyclin- 1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043437A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/09/2009 | WO2009043436A2 Use of af12198 as a therapeutic agent |
| 04/09/2009 | WO2009043170A1 Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors |
| 04/09/2009 | WO2009043116A1 Methods and compositions for the treatment of phosphatase- related disorders |
| 04/09/2009 | WO2009043106A1 Inorganic selenium and angiogenesis |
| 04/09/2009 | WO2009043093A1 Hif inhibition |
| 04/09/2009 | WO2009017777A3 Metabolites and derivatives of ambrisentan |
| 04/09/2009 | WO2009013596A3 Fortification of nutritional products with olive extracts containing hydroxytyrosol and hydroxytyrosol fortified nutritional products |
| 04/09/2009 | WO2009006089A3 A2 adenosine receptor agonists |
| 04/09/2009 | WO2009004999A8 Seamless capsule |